Search clinical trials for: CMAB807

Total 151 results

Taizhou Mabtech Pharmaceutical Co.,Ltd

Withdrawn

Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy Volunteers

Healthy Volunteers

China
Taizhou Mabtech Pharmaceutical Co.,Ltd

Recruiting

Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers

Healthy Volunteers

China
Taizhou Mabtech Pharmaceutical Co.,Ltd

Completed

Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers

Healthy Volunteers

China
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers

Postmenopausal Osteoporosis

China
Shanghai Biomabs Pharmaceutical Co., Ltd.

Recruiting

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .

Postmenopausal Osteoporosis

China
Taizhou Mabtech Pharmaceutical Co.,Ltd

Completed

The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity

Healthy Volunteers

China
Shanghai Zhangjiang Biotechnology Limited Company
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer (CRC009)

Metastatic Colorectal Cancer
M.D. Anderson Cancer Center

Recruiting

Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression

Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IV Colon Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Unresectable Colon Adenocarcinoma | Unresectable Rectal Adenocarcinoma

United States, Puerto Rico
M.D. Anderson Cancer Center

Recruiting

Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Richter Syndrome | Indolent Non-Hodgkin Lymphoma

United States
Taizhou Mabtech Pharmaceutical Co.,Ltd

Not yet recruiting

To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria
National Cancer Institute (NCI)

Completed

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

Acute Adult T-Cell Leukemia/Lymphoma | Adult T-Cell Leukemia/Lymphoma | Chronic Adult T-Cell Leukemia/Lymphoma | HTLV-1 Infection | Lymphomatous Adult T-Cell Leukemia/Lymphoma | Smoldering Adult T-Cell Leukemia/Lymphoma

United States
University of Washington
Bristol-Myers Squibb

Active, not recruiting

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma and other conditions

United States
M.D. Anderson Cancer Center

Active, not recruiting

Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal Carcinoma | Recurrent Primary Peritoneal...

United States
Mbarara University of Science and Technology
ANAMED

Completed

Evaluation of Artemisia Annua and Moringa

HIV Infections

Uganda
National Cancer Institute (NCI)

Recruiting

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Multiple Sclerosis | Rheumatoid Arthritis | Systemic Lupus Erythematosus | Psoriasis | Systemic Scleroderma | Crohn Disease | Ulcerative Colitis | Dermatomyositis | Psoriatic Arthritis | Inflammatory Bowel Disease | Autoimmune Disease | Sjogren...

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma | TFE3-Rearranged Renal Cell Carcinoma

United States, Puerto Rico
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States
M.D. Anderson Cancer Center

Withdrawn

Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

Resectable Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Recurrent Hodgkin Lymphoma | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Recurrent Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Plasma Cell Myeloma | Myeloproliferative Neoplasm | Recurrent... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Peritoneal Carcinomatosis | Malignant Peritoneal Neoplasm | Recurrent Endometrial Carcinoma | Stage IVB Uterine Corpus Cancer AJCC v8 | Recurrent Cervical Carcinoma | Metastatic Malignant Female... and other conditions

United States
Emory University
National Cancer Institute (NCI); Prostate Cancer Foundation

Recruiting

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Taizhou Mabtech Pharmaceutical Co.,Ltd

Recruiting

Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients

Crohn Disease

China
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD

Wet Age-related Macular Degeneration

China
National Cancer Institute (NCI)

Active, not recruiting

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Unresectable Cutaneous Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Mucosal Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma

Metastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Uterine Corpus Leiomyosarcoma

United States
National Cancer Institute (NCI)

Withdrawn

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Hematopoietic and Lymphoid Cell Neoplasm | Lynch Syndrome | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central... and other conditions

United States, Canada
Taizhou Mabtech Pharmaceutical Co.,Ltd

Terminated

Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC

Squamous Cell Carcinoma of the Head and Neck

China
Mayo Clinic

Recruiting

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Malignant Solid Neoplasm | Renal Cell Carcinoma | Hepatocellular Carcinoma | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Lung Non-Small Cell Carcinoma | Urothelial Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Recurrent Head and Neck Squamous... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

Stage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Pleomorphic Liposarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Metastatic Unresectable Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue Sarcoma | Metastatic... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

Acute Myeloid Leukemia

United States, Canada
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); Highlight Therapeutics

Active, not recruiting

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Leiomyosarcoma | Malignant Peripheral Nerve Sheath Tumor | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Undifferentiated High Grade Pleomorphic Sarcoma of Bone | Myxofibrosarcoma | Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the... and other conditions

United States
Mayo Clinic

Active, not recruiting

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Terminated

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Pleural Biphasic Mesothelioma | Pleural Sarcomatoid Mesothelioma

United States
Shanghai CP Guojian Pharmaceutical Co., Ltd.

Completed

Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma

Diffuse Large B Cell Lymphoma

China
Dwight Owen
National Cancer Institute (NCI)

Recruiting

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Plasmablastic Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Metastatic Neuroendocrine Neoplasm | Metastatic Neuroendocrine Carcinoma | Metastatic Large Cell Neuroendocrine Carcinoma | Metastatic Small Cell Neuroendocrine Carcinoma

United States, Canada
University of Washington

Completed

Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

Metastatic Malignant Neoplasm in the Bone | Salivary Gland Carcinoma | Metastatic Malignant Neoplasm in the Lung | Stage IV Major Salivary Gland Cancer AJCC v8 | Stage IVA Major Salivary Gland Cancer AJCC v8 | Stage IVB Major Salivary Gland Cancer AJCC v8 | Stage IVC Major Salivary Gland Cancer...

United States
University of Washington

Recruiting

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal Large B-Cell Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

United States
Emory University
National Cancer Institute (NCI); NovoCure Ltd.

Recruiting

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases

Metastatic Melanoma | Melanoma of Unknown Primary | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma | Metastatic Ocular Melanoma

United States

Search clinical trials for: CMAB807

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations